Pay in 4 interest-free payments of $27.45 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
33)29-14-21-4-2-3-9-26-21/h2-13
GO-6976 blocked neurotrophin-induced signaling and autophosphorylation of neurotrophin-specific tyrosine kinase (Trk) receptors
6R)-4-methoxy-16
Radotinib Catalog No.:M10972-2 Reversal of H3K9me2 by aRadotinib, also known as IY 5511, is an orally available, a second generation tyrosine kinase inhibitor of Bcr Abl fusion protein and the platelet derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR
US$ 205.55
US$ 135.50
US$ 173.00
US$ 55.16
US$ 89.98